The role of cannabinoids in neurodegenerative diseases.
An understanding of the actions of Cannabis (Marijuana) has evolved from folklore to science over the previous hundred years. This progression was spurred by the discovery of an endogenous cannabinoid system consisting of two receptors and two endogenous ligands. This system appears to be intricately involved in normal physiology, specifically in the control of movement, formation of memories and appetite control. As we are developing an increased understanding of the physiological role of endocannabinoids it is becoming clear that they may be involved in the pathology of several neurological diseases. Furthermore an array of potential therapeutic targets is being determined--including specific cannabinoid agonists and antagonists as well as compounds that interrupt the synthesis, uptake or metabolism of the endocannabinoids. This article reviews the recent progress in understanding the contribution of endocannabinoids to the pathology and therapy of Huntington's disease. Parkinson's disease, schizophrenia and tremor.
Glass
M
M
Department of Pharmacology, University of Auckland, New Zealand.
D000818:Animals; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D019636:Neurodegenerative Diseases / Q000503:physiopathology*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*
D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D018696:Neuroprotective Agents; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug